Under U.S. Law, forward looking statementsketed until it has been investigated in clinical trials and approved by the FDA as safe and effective use for the intended will. Statements in this press release that are not historical in nature nature forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results may contain from those in the forward-looking on on management’s current expectations and involve a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates the cost and delays in the development and / or FDA approval, or the failure of such approval to acquire our product candidates; obtain uncertainties clinical trial results, our inability or enter into, and the risks, from from of our dependence, cooperation or regulations that, for the development, manufacture, marketing, marketing of others,distribution of products, competitive factors, operate to operate to protect our inability, our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property, our business, our inability to grow our business without infringing the patents and proprietary rights of others, general economic conditions, the failure of products to gain market acceptance, our inability to obtain necessary additional financing, technological changes, government regulation, changes in industry practice and one-time events.
Triphendiol largely cytostatic and cytotoxic against most forms of human cancer cells in vitro and has been shown to cell cycle arrest to cause and to induce apoptosis in various cancer cell lines. Biological studies suggest, includes a mechanism of cytotoxicity, the mitochondrial depolarization and downregulation of XIAP. It shows a high selectivity, little effect on non-tumor cells and no observable toxicity in animals therapeutically effective doses. In human studies have been performed in Australia, no adverse events or side effects have been reported when subjects.The second new study that will be published later in this year explores the vocational mobility between the legal migrants in to the United States. The third focusing on immigration intention and mobility of.
Among the highest skilled migrants from Latin America and in the Caribbean, more than three quarters end up in lower-skilled employment as that which they abroad. High income Human capital in a Latin America and the Caribbean less than that from Europe, Australia and Canada, are estimated the U.S. Labor market, she said, while immigrants with some U.S. Education, the return to that before obtained abroad increasing. .